The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection-Reference-Cited by-同舟云学术

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection

Published:2021-10 Issue:10 Volume:10 Page:3929-3942
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Shi Jinpeng,Li Jiayu,Wang Qi,Cheng Xiaomin,Du He,Han Ruoshuang,Li Xuefei,Zhao Chao,Gao Guanghui,He Yayi,Chen Xiaoxia,Su Chunxia,Ren Shengxiang,Wu Fengying,Zhang Zhemin,Zhou Caicun

Publisher

AME Publishing Company

Subject

Oncology

Link

https://tlcr.amegroups.com/article/download/57172/pdf

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients;BMC Pulmonary Medicine;2024-04-12

2. Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor;Frontiers in Immunology;2024-01-17

3. Reativação de Tuberculose Pulmonar em uma Paciente com Câncer de Orofaringe Tratada com Nivolumabe: Relato de Caso;Revista Brasileira de Cancerologia;2024-01-12

4. The expression of miR-21, HSP90a and gGASP-1 in serum of patients with lung cancer and their correlation with pathological subtypes;Journal of Medical Biochemistry;2024

5. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study;Journal of Thoracic Disease;2023-10